Literature DB >> 8777723

Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages.

C C Norbury1, L J Hewlett, A R Prescott, N Shastri, C Watts.   

Abstract

Extracellular proteins are not generally presented on class I MHC molecules in vitro, yet many studies show that a pathway exists in vivo for the presentation of extracellular material on class I molecules to prime CD8+ T cell responses. Here, we provide morphological evidence that proteins taken up by macropinocytosis can gain access to the cytosol and therefore into the conventional class I MHC pathway. Class I presentation of soluble ovalbumin by mouse bone marrow macrophages was dramatically enhanced by MCSF or phorbol ester and blocked by amiloride, which stimulate and inhibit membrane ruffling and macropinocytosis, respectively. Brefeldin A, gelonin, and a peptide aldehyde inhibitor of proteasomal processing each blocked presentation of macropinocytosed antigen, demonstrating that unusual access to the conventional class I MHC pathway was occurring. This novel cell type-specific endocytic pathway may facilitate presentation of exogenous material on class I MHC molecules, allowing induction of CD8+ T cell responses to soluble proteins, tumor cell fragments, and some pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8777723     DOI: 10.1016/1074-7613(95)90067-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  114 in total

Review 1.  Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.

Authors:  M Vukmanovic-Stejic; M J Thomas; A Noble; D M Kemeny
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

2.  Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.

Authors:  J T Voeten; G F Rimmelzwaan; N J Nieuwkoop; R A Fouchier; A D Osterhaus
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

3.  A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels.

Authors:  Niren Murthy; Mingcheng Xu; Stephany Schuck; Jun Kunisawa; Nilabh Shastri; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

4.  Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus.

Authors:  Yunjung Cho; Sameh Basta; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C.

Authors:  M Amyere; B Payrastre; U Krause; P Van Der Smissen; A Veithen; P J Courtoy
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 6.  Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

Authors:  Nicole Selenko; Otto Majdic; Ulrich Jäger; Christian Sillaber; Johannes Stöckl; Walter Knapp
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

Review 7.  Cross-presentation: dendritic cells and macrophages bite off more than they can chew!

Authors:  Sven Brode; Paul A Macary
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 8.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 9.  Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis.

Authors:  Sasha A Doodnauth; Sergio Grinstein; Michelle E Maxson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

10.  Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.

Authors:  V Maréchal; M C Prevost; C Petit; E Perret; J M Heard; O Schwartz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.